+Vote!
DeepMarket Stock Market Blog (Free subscription) | 23/12/2008
Seasonal Patterns found for the following stocks: Alkermes Inc (ALKS) over the next 10 trading days. Look at the seasonal patterns for Alkermes Inc in context. Comarco Inc (CMRO) over the next 8 trading days. Look at the seasonal patterns for Comarco Inc in context. Cintas Corp (CTAS) over the next 10 trading days. Look [...]
+Vote!
BloggingStocks (Free subscription) | 19/12/2008
Filed under: Analyst reports , Analyst upgrades and downgrades , eBay (EBAY) , Amazon.com (AMZN) , Expedia Inc (EXPE) , FedEx Corp (FDX) , Analyst initiations Analyst upgrades: Jefferies upgraded shares of Alkermes (NASDAQ: ALKS ) to Overweight from Neutral on valuation, as they believe the current share price undervalues Risperdal Consta and provides little to no value for other pipeline drugs. JP...
+Vote!
StreetInsider.com News Articles (Free subscription) | 19/12/2008
UPGRADES: Jefferies & Co upgrades Alkermes (Nasdaq: ALKS) from Hold to Buy. J.P. Morgan upgrades Assurant (NYSE: AIZ) from Neutral to Overweight. J.P. Morgan upgrades ASML Holding (Nasdaq: ASML) from Neutral to Overweight. For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades DOWNGRADES: Citi downgrades Fluor (NYSE: FLR) from Hold to Sell. Price target lowered from $41 to $37. Despite...
1Vote!
Medical News Today (Free subscription) | 07/12/2008
Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system (CNS) disorders. ALKS 33 is the company's first novel, small molecule drug candidate to enter the clinic. The molecule builds on Alkermes' scientific expertise in brain reward pathways as well as the company's...
+Vote!
The Boston Business Journal (Free subscription) | 04/12/2008
Building on its expertise in brain reward pathways, Alkermes has launched a clinical trial of two possible treatments for addictive disorders.
+Vote!
Business Wire (Free subscription) | 04/12/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous
+Vote!
Xconomy (Free subscription) | 03/12/2008
Several of the Boston area’s public life sciences companies were making news this week. But first… —Ryan delved into the strategy and portfolio of Partners Innovation Fund, which was launched last year by Massachusetts General and Brigham and Women’s hospitals to invest exclusively in startups with science from the two Harvard-affiliated hospitals. Among the startups [...]
+Vote!
The Boston Business Journal (Free subscription) | 01/12/2008
Alkermes Inc. (Nasdaq: ALKS) will take up the manufacture of Vivitrol, a drug for the treatment of alcohol abuse.
+Vote!
Business Week (Free subscription) | 01/12/2008
S&P Picks and Pans: Yahoo, eBay, Ford, Johnson & Johnson, AlkermesAnalysts' opinions on stocks in the news Monday From Story Tools S&P REITERATES BUY OPINION ON SHARES OF YAHOO INC. (; 11.51): An unconfirmed report in The Times of London states that YHOO is in talks to sell its search business to Microsoft (; 20.22) for some $20 billion. We think that even though such a transaction would make sense...
+Vote!
The Philadelphia Business Journal (Free subscription) | 01/12/2008
Cephalon Inc. said Monday it has ended its collaboration with Alkermes Inc., under which the two companies were co-promoting Vivitrol, an injectable drug used developed by Alkermes and used to treat alcohol dependence. (CEPH) (ALKS)
+Vote!
Business Wire (Free subscription) | 25/11/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by JPMorgan on Friday, December 5, 2008 at 12:45 p.m. EST. The presentation will be
+Vote!
Business Wire (Free subscription) | 24/11/2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by NASDAQ International on Thursday, December 4, 2008 at 1:45 p.m. GMT (8:45 a.m.
1Vote!
Medical News Today (Free subscription) | 19/11/2008
Alkermes, Inc. (NASDAQ: ALKS) today announced positive preclinical results for its proprietary small molecule candidate, RDC-1036, which emerged from a library of novel opioid modulators. The data demonstrated RDC-1036 was effective in reversing opioid effects on gastrointestinal motility. Data also showed that oral administration of RDC-1036 had greater efficacy at a lower dose and for an extended...
